Tracer library / [161Tb]Tb-crown
[161Tb]Tb-crown
Also written as [Tb-161]Tb-crown
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 4
What it is
- Compound class
- crown-αMSH (macrocyclic crown chelator conjugated to alpha-melanocyte-stimulating hormone peptide)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| miniAllinOne Trasis | custom manifold | SPE | — decay-corrected | 99.9939 | crown-αMSH | 36459299 2022 EJNMMI Radiopharm Chem The process outlined in Fig. 3d was automated using a TRASIS Mini AiO module (Fig. 4). |
| Manual synthesis | — | SPE | 90 | — | crown-αMSH | 36459299 2022 EJNMMI Radiopharm Chem We also tried performing purification entirely manually, and the results show better overall removal of Gd (2.3 ng for 75 MBq 161Tb). - 190 MBq of unpurified 161Tb was successfully purified with an activity recovery 90% (1.08 MBq/µL at EOS). |
| — | custom manifold | HPLC | — decay-corrected | 99.9947 | crown-αMSH | 36459299 2022 EJNMMI Radiopharm Chem One portion was purified using the HPIC method (Cassells et al. 2021) at the Belgian Nuclear Research Center (SCK CEN). |
| Manual synthesis | — | — | 85.5 ± 5.0% | — | crown-4Py | 35704752 2022 Inorg Chem A 10 μL aliquot of the respective chelator, or deionized water as a negative control, was further diluted with 80 μL of deionized water and for 203Pb labeling studies, [203Pb]Pb(OAc)2 (85 kBq, 10 μL, 1 M NH4OAc, pH 7) was added and mixed at ambient temperature to begin the reaction. - The RCYs for crown-4Py at concentrations between 10−4 and 10−7 M were 85.5 ± 5.0%, 45.3 ± 1.4%, 2.0 ± 3.5%, and 0%, respectively. |
Need this precursor?We can point you to suppliers for [161Tb]Tb-crown, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36459299: 'biodistribution of [161Tb]Tb-crown-αMSH'. Stage set/updated at stage 39 from PMID 37049918: 'Preclinical Evaluation of [155/161Tb]Tb-Crown-TATE-A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours.'.